Kilitch Drugs (India) delivered exceptional financial results for the quarter ended March 2026, with consolidated net profit surging 39.62% to ₹14.52 crore compared to ₹10.40 crore in the corresponding quarter of the previous year. According to reports from Business Standard, the pharmaceutical company's sales revenue increased by 46.33% to ₹89.60 crore during the March 2026 quarter, up from ₹61.23 crore in the same period last year. The company's operating profit margin (OPM) improved to 24.72% in the current quarter, demonstrating enhanced operational efficiency. As per recent analysis, the quarterly revenue of ₹89.60 crores represents the highest quarterly sales figure in at least eight quarters, driven by what appears to be a strong seasonal uptick, though the dramatic 66.51% sequential jump from Q3 FY26's ₹53.81 crores raises questions about revenue sustainability.
For the full financial year ended March 2026, Kilitch Drugs (India) maintained strong growth momentum with net profit rising 13.00% to ₹30.17 crore compared to ₹26.70 crore in the previous year. As reported by Business Standard, the company's annual sales revenue grew 18.73% to ₹235.47 crore in FY2026, up from ₹198.32 crore in FY2025. The company's profit before depreciation and tax (PBDT) increased by 13% to ₹42.28 crore for the full year, while profit before tax (PBT) rose 12% to ₹38.65 crore. The five-year compound annual growth rate for sales stands at a robust 28.03%, while EBIT has grown at an impressive 91.88% over the same period, indicating improving operational leverage.
The company's operating profit before depreciation, interest, and tax (excluding other income) surged to ₹22.14 crores from ₹6.16 crores in Q3 FY26, translating to an operating margin of 24.71%—the highest level in eight quarters and approaching the company's historical best performance from March 2025. The net profit margin expanded to 16.61% from 8.03%, reflecting improved operational efficiency and better absorption of fixed costs on higher revenue base. The interest coverage has strengthened considerably, with the operating profit-to-interest ratio reaching 15.38 times in Q4 FY26, the highest in the trailing eight quarters. However, the company has demonstrated wild swings in profitability, with net profit oscillating between ₹3.03 crores in June 2025 and ₹14.52 crores in March 2026 over just three quarters, making earnings forecasting challenging and raising questions about sustainability.
Despite the strong quarterly performance, the stock, trading at ₹153.00 as of May 15, 2026, has declined 1.61% following the results announcement, reflecting investor scepticism despite the strong quarterly showing. Over the past year, shares have tumbled 26.10%, significantly underperforming both the Sensex (down 8.84%) and the broader pharmaceuticals sector (up 11.67%) by a substantial margin of 37.77 percentage points. The company's P/E ratio of 20.44 times appears reasonable relative to peers, well below the pharmaceutical industry average of approximately 72 times, though the low ROE of 7.61% and ROCE of 10.22% indicate the business struggles to generate adequate returns for shareholders. The enterprise value-to-EBITDA multiple of 18.21 times and EV-to-EBIT of 20.70 times suggest limited margin of safety at current prices, with the stock's high beta of 1.50 making it a higher-risk proposition.
